Filing Flows › Gilead Sciences (GILD) › Q1 2026
Gilead Sciences (GILD) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Gilead Sciences (GILD) reported revenue of $7.0B for the first quarter 2026 (Q1 2026), +4% from a year earlier and -12% from the quarter before. Operating margin was 37.2%, net earnings $2.0B (29.0% of revenue).
Gilead Sciences, Q1 2026: revenue $7.0B (+4% year over year), operating margin 37.2%, net earnings $2.0B, operating cash flow $2.5B. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.0B | -12% | +4% |
| Operating profit | $2.6B | +30% | +16% |
| Net earnings | $2.0B | -7% | +54% |
| Operating cash flow | $2.5B | -24% | +45% |
| Free cash flow | $2.4B | — | +47% |
What changed
Revenue was $7.0B in Q1 2026, up 4% year over year and down 12% from the previous quarter. Biktarvy was the largest line at 48% of revenue. Biktarvy added $0.21B year over year (up 7%), 72% of the total change. Genvoya declined 27%.
Operating profit was $2.6B, a 37.2% margin (up 3.6 points year over year). Of the extra revenue versus Q1 2025, 119% reached operating profit, above the 34% margin then. Total costs fell 1% while revenue rose 4%. The fastest-growing cost line was SG&A (+15%). Net earnings were $2.0B, up 54% year over year. The effective tax rate was 21.7%.
Operating cash flow was $2.5B (up 45% year over year), 126% of net earnings. Non-cash charges added back $0.09B of depreciation and $0.22B of share-based compensation. Working capital and other items added $0.21B. After purchases of property, plant and equipment ($0.12B), free cash flow as the company reports it was $2.4B.
Questions
What was Gilead Sciences' revenue in the first quarter 2026?
Gilead Sciences (GILD) reported revenue of $7.0B for the first quarter 2026 (Q1 2026), +4% from a year earlier and -12% from the quarter before.
Was Gilead Sciences profitable in the first quarter 2026?
Operating profit was $2.6B (37.2% of revenue) and net earnings $2.0B.
Source: Gilead Sciences 10-Q on SEC EDGAR.